Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 12:23pm CET

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
01:47p ASTRAZENECA : CHMP positive opinion for ZS-9 in hyperkalaemia
01:41p ASTRAZENECA : Gets Positive Opinion On ZS-9 In Hyperkalaemia
02/23 ASTRAZENECA : Phase III breast cancer trial met primary endpoint
02/21 ASTRAZENECA : Drugs giant in new rights deal
02/21 ASTRAZENECA : *berenberg cuts astrazeneca price target to 5450 pence - 'buy'
02/21 ASTRAZENECA : in $320m cancer treatment deal
02/21 ASTRAZENECA : County surveyor looks to resolve ditch issues
02/20 ASTRAZENECA : selling U.S., Canadian rights to cancer drug
02/20 British FTSE 100 decreases 0.34 pct on Thursday
02/20 LONDON MARKET PRE-OPEN : Stocks Seen Up; AstraZeneca Signs Deal In US
More news
Sector news : Pharmaceuticals - NEC
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/23 Is Pfizer's Research Pipeline Truly Undervalued?
02/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2016 Update
02/22 Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
02/22 Chi-Med Looks Outside Its Comfort Zone
02/22 Tersera Gives Zoladex A Life After Death
Financials ($)
Sales 2017 21 588 M
EBIT 2017 5 790 M
Net income 2017 2 747 M
Debt 2017 11 853 M
Yield 2017 4,79%
P/E ratio 2017 25,73
P/E ratio 2018 20,98
EV / Sales 2017 3,91x
EV / Sales 2018 3,80x
Capitalization 72 464 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 62,7 $
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.74%331 089
ROCHE HOLDING LTD.5.98%209 906
PFIZER INC.3.42%206 688
NOVARTIS AG3.51%201 806
MERCK & CO., INC.10.91%181 558
More Results